The Worst Biotech CEO of 2013 is Vijay Samant of Vical (VICL).
Samant wins this year's (dis)honor for putting melanoma patients in harm's way by delaying the analysis of Vical's allovectin phase III study. When Samant finally got around to announcing the study results -- years later than expected -- melanoma patients treated with allovectin fared worse than patients treated with conventional chemotherapy.
It takes a special kind of moral bankruptcy to cause more pain and suffering to already critically sick melanoma patients, but that's kind of biotech CEO Samant is, so the award is well deserved.
Someone out there is particularly angry at Samant because he won with an astonishing 71% of the 14,140 votes cast.
The runner-up this year was Ariad Pharma's (ARIA) Harvey Berger with 14% of the votes cast. Aveo Pharma's (AVEO) Tuan Ha Ngoc, John Johnson of Dendreon (DNDN) and Amarin's (AMRN) Joe Zakrzewaski placed third, fourth and fifth, respectively.
A special shout-out of Zakrzewski for announcing his "retirement" from Amarin on Monday.
This year's Best Biotech CEO was Celgene's (CELG) Bob Hugin.
-- Reported by Adam Feuerstein in Boston.
Follow Adam Feuerstein on Twitter.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV